A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Completed · Phase 3 · NCT05601882
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $105,028
- U.S. investigators named
- 15
- Sites paid
- 15
- Planned or actual enrollment
- 920
About the trial
- Sponsor
- AbbVie
- Tested
- Dupilumab (drug), Upadacitinib (drug)
- Dates
- Started 2022-11-28; completion 2024-08-08
- Results posted
- Yes
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to systemic therapies. Adverse events and change in the disease activity will be assessed. Upadacitinib and dupilumab are approved drugs for the treatment of moderate to severe atopic dermatitis (AD). The study is comprised of a 35-day Screening Period, a 16-week treatment Period 1 and a 16-week treatment Pe…
From ClinicalTrials.gov, last updated 2025-02-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $105,028 in research payments for this study in 2025 (22 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Dowling B. Stough IV, MD Dermatology · Hot Springs, AR
- Sadra S. Jazayeri, MD Dermatology · Phoenix, AZ
- Navid Ezra, M.D. Dermatology · Thousand Oaks, CA
- Vivian Laquer, M.D. Dermatology · Irvine, CA
- Christopher G. Bunick, M.D., PH.D. Dermatology · New Haven, CT
- Tory Sullivan, M.D. Dermatology · North Miami Beach, FL
- Scott A. Fretzin, M.D. Dermatology · Indianapolis, IN
- Victoria Kuohung, MD Dermatology · Quincy, MA
- Neetu Talreja, MD Hospitalist · Detroit, MI
- Melody Stone, MD Dermatology · Saint Joseph, MO
- Craig A. Rohan, MD Dermatology · Wright Patterson Afb, OH
- Iftikhar Hussain, MD Allergy & Immunology · Tulsa, OK
- Jose R. Gonzalez Chavez, M.D. Dermatology · Santurce, PR
- John C. Browning, MD Dermatology · San Antonio, TX
- Angela Y. Moore, MD, PA Dermatopathology · Arlington, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gcm Medical Group Psc $21,385
- Dawes Fretzin Clinical Research $20,748
- Treasure Valley Medical Research $17,672
- Tory Sullivan MD PA $11,481
- Vital Prospects Clinical Research $6,034
- Medisearch Clinical Trials $5,000
- Wright State Physicians Inc $4,491
- Texas Dermatology and Laser $4,384
- Clinical Trials Institute Of $3,560
- Yale University $3,250
- Beacon Clinical Research LLC $2,256
- Arlington Research Center Inc $1,750
- Clinical Trials Research Institute $1,500
- First Oc Dermatolgy Research Inc $992
- Alliance Dermatology & Mohs Center $526
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.